TESARO (TSRO) Misses Q4 EPS by 30c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
TESARO Announces Fourth-Quarter 2014 Operating Results
February 19, 2015 4:01 PM ESTEnrollment in niraparib NOVA non-gBRCA cohort on track to complete during Q1 2015 New QUADRA trial of niraparib for the treatment of ovarian cancer to begin in Q1 2015 U.S. FDA PDUFA action date for oral rolapitant is September 5, 2015 Cash and cash equivalents totaled approximately $257 Million as of December 31, 2014
WALTHAM, Mass., Feb. 19, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq: TSRO), an oncology-focused biopharmaceutical company, today reported financial results for fourth-quarter and full-year 2014 and provided an update on the Company's... More
